Clinical Study Results
Research Sponsor: MedImmune LLC, a wholly owned subsidiary of AstraZeneca
Drugs Studied:
- Durvalumab 
- Oleclumab
- Monalizumab 
- Danvatirsen
Study Purpose: This study was done to learn how well durvalumab, when given alone or with another treatment, works in participants with early stage non-small cell lung cancer
Protocol Number: D9108C00002

Thank you!
Thank you to the participants who took part in this clinical study. All of the participants helped researchers learn more about how well durvalumab, when given alone or with another treatment, works in people with early stage non-small cell lung cancer, also called "NSCLC".

MedImmune LLC, a wholly owned subsidiary of AstraZeneca, sponsored this study and believes it is important to share the results of the study with you and the public. An independent non-profit organization called CISCRP helped prepare this summary of the study results for you. We hope it helps you understand and feel proud of your important role in medical research.

If you participated in the study and have questions about the results, please speak with the study doctor or staff at your study site.